Prospective multicenter randomized patient recruitment and sample collection to enable future measurements of sputum biomarkers of inflammation in an observational study of cystic fibrosis

Table 5 Collections

Collection Type	Enrollment	First Pulmonary Exacerbation Onset^a	First Pulmonary Exacerbation Convalescence	Additional Exacerbation	End of Study Follow Up^b
Clinical Data	114	92	36	10	72
Samples	114^c	52	29	8	62

^aFollow up varied and sometimes exceeded one year to the first exacerbation. Among enrolled patients, 81% had an exacerbation during the study. However, the observed percentage of patients with exacerbations within 1 year was lower, 47%, and was similar to the 44% reported in annualized 2014 CFFPR data for this cohort of patients (Table 4)
^bQueries for data from the end-of-study are ongoing at the time of submission
^c114 samples were collected, however, only 112 were sufficient in size to allow laboratory analyses

ISSN: 1471-2288